Evidence map›Paper›PMID 41261778›Full record

ArticleThoracic cancer2025

Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer.

Maja Guberina, Martin Metzenmacher, Christoph Pöttgen, Marcel Wiesweg, Nika Guberina, Anja Merkel-Jens, Diana Lütke-Brintrup, Servet Bölükbas, Wilfried E E Eberhardt, Georgios Stamatis and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Maja GuberinaDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
Martin MetzenmacherMedical Faculty, University Duisburg-Essen, Essen, Germany.
Christoph PöttgenDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
Marcel WieswegMedical Faculty, University Duisburg-Essen, Essen, Germany.
Nika GuberinaDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
Anja Merkel-JensInstitute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany.
Diana Lütke-BrintrupMedical Faculty, University Duisburg-Essen, Essen, Germany.
Servet BölükbasMedical Faculty, University Duisburg-Essen, Essen, Germany.
Wilfried E E EberhardtMedical Faculty, University Duisburg-Essen, Essen, Germany.
Georgios StamatisMedical Faculty, University Duisburg-Essen, Essen, Germany.
Fabian DoerrMedical Faculty, University Duisburg-Essen, Essen, Germany.
Till PlönesDepartment of Thoracic Surgery, Fachkrankenhaus Coswig, Lung Center, Coswig, Germany.
Christian HoffmannDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
Gregor ZaunMedical Faculty, University Duisburg-Essen, Essen, Germany.
Benedikt HöingMedical Faculty, University Duisburg-Essen, Essen, Germany.
Cornelius KürtenMedical Faculty, University Duisburg-Essen, Essen, Germany.
Emil MladenovDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
George IliakisDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
David KerstingMedical Faculty, University Duisburg-Essen, Essen, Germany.
Wolfgang P FendlerMedical Faculty, University Duisburg-Essen, Essen, Germany.
Thomas GaulerDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
Marcel OpitzMedical Faculty, University Duisburg-Essen, Essen, Germany.
Aleksandar MilosevicMedical Faculty, University Duisburg-Essen, Essen, Germany.
Michael ForstingMedical Faculty, University Duisburg-Essen, Essen, Germany.
Felix NensaMedical Faculty, University Duisburg-Essen, Essen, Germany.
Lale UmutluMedical Faculty, University Duisburg-Essen, Essen, Germany.
Faustina FunkeMedical Faculty, University Duisburg-Essen, Essen, Germany.
Hubertus HautzelMedical Faculty, University Duisburg-Essen, Essen, Germany.
Ken HerrmannMedical Faculty, University Duisburg-Essen, Essen, Germany.
Christian TaubeMedical Faculty, University Duisburg-Essen, Essen, Germany.
Dirk TheegartenMedical Faculty, University Duisburg-Essen, Essen, Germany.
Clemens AignerDepartment of Thoracic Surgery, University Medicine Essen - Ruhrlandklinik, Essen, Germany.
Martin SchulerMedical Faculty, University Duisburg-Essen, Essen, Germany.
Martin StuschkeDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo analyze the association of pathologic-complete-response (PCR) and survival after neoadjuvant concurrent chemo-radiotherapy, we evaluated a large cohort of patients with potentially resectable stage IIIA-IIIC non-small cell lung cancer (NSCLC) treated with a trimodality approach.

methodsConsecutive patients underwent neoadjuvant induction chemotherapy, followed by concurrent chemo-radiotherapy and surgery. Patients received established imaging, and diagnostics. Leave-one-out cross-validation was employed to identify the most effective prognostic classifier.

resultsAltogether, 403 patients treated between 06/2000 and 01/2020 were included. Median follow-up was 111 months (IQR: 71-127 months). PCR was achieved in 34% (137 patients) after neoadjuvant therapy and major-pathologic response without PCR in 30% (MPR

conclusionsInduction chemotherapy followed by chemo-radiotherapy results in high PCR rates. In this investigation, PCR is followed by high event-free and overall survival rates. These data warrant further investigation of chemo-radiotherapy as a significant component of neoadjuvant treatment regimens in trials combined with immunotherapy. This strategy may increase the PCR rates, particularly for patients with more advanced, potentially resectable stage III NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungChemoradiotherapyInduction ChemotherapyLung NeoplasmsNeoadjuvant TherapyAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPathologic Complete ResponsePrognosisinduction chemo‐radiotherapymajor pathological responsepathologic complete responsepotentially resectable stage III NSCLCpredictor of survival

Identifiers

PMID41261778
PMCPMC12630550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.